AVITA Medical, Inc. (RCEL) · Nov 2, 2026 · Share issuance
387,716 shares issued — Cashless exercise; 387,716 shares issued
AVITA Medical disclosed a warrant exercise tied to its 2026 debt facility. The cashless transaction adds dilution but changes little operationally.
AVITA Medical is in a commercial scaling phase led by RECELL, with Cohealyx and PermeaDerm expanding the acute-wound-care portfolio; the company recently raised 2026 revenue guidance to $86–89 million and expects cash-flow breakeven in the fourth quarter.
This filing completes a financing obligation, not a business milestone. Perceptive exercised the warrant that was granted as part of AVITA’s previously disclosed five-year secured credit facility, so the existence of the potential dilution was already known. The underlying facility provided up to $60 million, including $50 million initially funded. 〔0〕
The only new economic detail is mechanical dilution without proceeds. Perceptive used a cashless exercise: AVITA withheld 112,284 shares for the exercise price and issued 387,716 shares. 〔1〕 That is roughly 1.3% of the 30.8 million shares outstanding at the June 2026 annual meeting, but it does not extend liquidity or accelerate commercialization.
Bottom line: This is expected financing cleanup with modest dilution and no new cash. It barely changes AVITA’s operating story or its path toward revenue growth and breakeven.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!